Hauppauge, NY, August 12, 2004 —Sunrise Medical Laboratories, Inc. today becomes the first New York-area reference laboratory to offer Imaging-Directed Cytology (IDC) for cervical cancer screening. The FDA approved ThinPrep Imaging System combines revolutionary imaging technology with human interpretive expertise to provide dual review of all ThinPrep Pap tests. The system improves cervical cancer screening efficiency and performance.
“Sunrise Medical Laboratories is committed to providing clinicians with leading edge technology to detect disease early and the ThinPrepâ System enables us to do that,” said Larry Siedlick, CEO of Sunrise Medical Laboratories. “Sunrise becomes the first major laboratory to be offering a dual review of Pap smears on a routine basis. We believe this technology will raise the standard of care for patients and achieve a higher level of certainty in cervical cancer screening.”
According to the National Cancer Institute, approximately 15,000 women in the United States are diagnosed with cervical cancer each year and about 5,000 die of the disease. Cervical cancer is almost 100 percent curable if detected early. More than 30 published studies with more than 500,000 patients have demonstrated the improved performance of the ThinPrep Pap Test compared to the conventional Pap smear.
About Sunrise Medical Laboratories, Inc.:
Founded in 1972, Sunrise Medical Laboratories is the leading regional provider of diagnostic lab services for physicians and hospitals, offering advanced biomedical testing services that support the prevention, diagnosis and treatment of medical diseases. Sunrise is also the industry leader in laboratory-physician computer links with its trademarked SunData xT ä System.
Sunrise Medical Laboratories employs over 300 professionals and provides services through an extensive courier network as well as at Patient Service Centers throughout the New York metropolitan area.